Bank of Montreal’s Vaxcyte PCVX Stock Holding History

Bank of Montreal’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31,547	Closed	-$1.03M	–	3745
2025 Q2	$1.03M	Buy	31,547 +1,274	+4%	+$41.8K	﹤0.01%	1894
2025 Q1	$1.14M	Buy	30,273 +6,400	+27%	+$512K	﹤0.01%	1754
2024 Q4	$1.95M	Sell	23,873 -3,560	-13%	-$353K	﹤0.01%	1560
2024 Q3	$3.1M	Buy	+27,433	New	+$2.47M	﹤0.01%	1504
2022 Q2	–	Sell	-11,019	Closed	-$269K	–	4343
2022 Q1	$269K	Sell	11,019 -37	-0.3%	-$808	﹤0.01%	3256
2021 Q4	$281K	Buy	11,056 +120	+1%	+$2.79K	﹤0.01%	2766
2021 Q3	$286K	Buy	10,936 +597	+6%	+$14.5K	﹤0.01%	3158
2021 Q2	$249K	Buy	10,339 +1,615	+19%	+$33.1K	﹤0.01%	3133
2021 Q1	$181K	Buy	8,724 +1,481	+20%	+$37.3K	﹤0.01%	3158
2020 Q4	$194K	Buy	7,243 +6,399	+758%	+$238K	﹤0.01%	3225
2020 Q3	$44K	Buy	+844	New	+$33.6K	﹤0.01%	3492

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bank of Montreal's PCVX Position: Q3 2025 in Review

Bank of Montreal sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 31,547 shares — an estimated $1.03M sold.

Bank of Montreal first reported a position in PCVX in Q3 2020 and held it in 11 quarters. The position peaked at $3.1M in Q3 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

Bank of Montreal reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
Bank of Montreal sold 31,547 Vaxcyte shares in Q3 2025, an estimated $1.03M.
Bank of Montreal first reported a position in Vaxcyte in Q3 2020 and held it in 11 quarters.
Bank of Montreal's Vaxcyte position peaked at $3.1M in Q3 2024.
285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Bank of Montreal's 13F filing for Q3 2025, filed 13 Nov 2025.